Effect of TACE Combined with Stereotactic Body X-knife on the Patients with Hepatocellular Carcinoma

Jun ZENG,Li-hua TAN,Yu-zhi WU,Yang-yu GUO,Xiu-gen FU
DOI: https://doi.org/10.13241/j.cnki.pmb.2018.13.014
2018-01-01
Abstract:Objective: To discuss the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with stereotactic X-knife in the treatment of liver cancer. Methods: 120 patients with primary liver cancer were selected from December2015 to August 2017 in our hospital. The patients were randomly divided into X-group, TACE group and combined group, each group had a total of 40 patients. X-knife group patients were treated with X-knife, TACE group was treated with TACE alone, and the combination group was treated with X-knife combined with TACE. The clinical effect, survival time, liver function before and after treatment and the occurrence of toxic side effects were compared among the three groups. Results: The total effective rate of combined group was 47.5%, which was significantly higher than that of the X-knife group and the TACE group (P<0.05). The total effective rate of X-knife group was 27. 5%, which was significantly higher than that of TACE group (P<0.05). The survival time of the combined group was (0.73±0.18) years, (0.48±0.18) years, (1.10±0.22) years, and the survival time of the combined group was significantly longer than that in the X-knife group and TACE group (P<0.05), the survival time of the X-knife group was longer than that in TACE group (P <0.05). The level of Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma-glutamyl transpeptidase (γ-GT) and total bilirubin (TBil) were significantly lower than those before treatment (P<0.05). The level of serum ALT and AST after treatment in the combined group were no significant difference with TACE group or X-knife group (P>0.05), but the level of serum γ-GT and TBil was significantly lower than that of TACE group and X-knife group (P<0.05). There was no significant difference in the toxic and side effects among the three groups (P>0.05). Conclusion: The clinical efficacy of TACE combined with stereotactic X-knife is superior to TACE or X-knife alone in the treatment of liver cancer, and the safety of three treatments is equal.
What problem does this paper attempt to address?